To assess the prevalence of NKG2A+ and NKG2C+ biases across different cancer types, we measured the percentages of NKG2A+ and NKG2C+ CD8+ T cells in cancer types for which we had large numbers of patients with single-cell data. This evidence concerns the gene CD8A and cancer.